PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

@article{Ansell2015PD1BW,
  title={PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.},
  author={Stephen M Ansell and Alexander M Lesokhin and Ivan Borrello and Ahmad S Halwani and Emma C Scott and Mart{\'i}n Guti{\'e}rrez and Stephen J. Schuster and Michael M. Millenson and Deepika Cattry and Gordon J Freeman and Scott J Rodig and Bjoern Chapuy and Azra Hadi Ligon and Lili L Zhu and Joseph F. Grosso and Su Young Kim and John M. Timmerman and Margaret A Shipp and Philippe F Armand},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 4},
  pages={311-9}
}
BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune detection. In classic Hodgkin's lymphoma, alterations in chromosome 9p24.1 increase the abundance of the PD-1 ligands, PD-L1 and PD-L2, and promote their induction through Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling. We hypothesized that nivolumab, a PD-1-blocking antibody, could inhibit tumor immune evasion in patients with… CONTINUE READING